10-K: Integrated BioPharma Reports Slight Revenue Dip but Achieves Net Income in Fiscal Year 2024

Integrated BioPharma experienced a minor decrease in revenue but achieved net income in fiscal year 2024, according to its latest 10-K filing.

Summary

• Integrated BioPharma, Inc. reported a slight decrease in net sales, from $50.67 million in fiscal year 2023 to $50.32 million in fiscal year 2024.
• The company's gross profit decreased to $3.88 million in fiscal year 2024 from $4.06 million in the previous year.
• Operating income increased to $251,000 in fiscal year 2024, compared to $120,000 in fiscal year 2023.
• Net income was $112,000 in fiscal year 2024, a significant improvement from a net loss of $34,000 in fiscal year 2023.
• The company's revenue is heavily concentrated, with approximately 90% of consolidated net sales coming from two customers in the Contract Manufacturing segment.
• The company is experiencing negative impacts on margins due to inflation and tightened labor markets.
• The company has a $5 million senior secured financing facility available, with no amounts outstanding as of June 30, 2024.
• The company had approximately 147 full-time employees as of September 20, 2024, with 112 being members of the Teamsters Union.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company returned to profitability and reduced expenses, it faces significant risks related to customer concentration, supply chain issues, and economic conditions. The sentiment is cautiously optimistic.

Positives

• The company achieved net income of $112,000 in fiscal year 2024, a significant improvement from a net loss of $34,000 in fiscal year 2023.
• Operating income increased to $251,000 in fiscal year 2024, compared to $120,000 in fiscal year 2023.
• Selling and administrative expenses decreased by 7.8% in fiscal year 2024.
• The company has a $5 million senior secured financing facility available, providing financial flexibility.
• The company's cash position increased to $1.68 million at the end of fiscal year 2024 from $1.32 million at the end of fiscal year 2023.

Negatives

• Net sales decreased slightly to $50.32 million in fiscal year 2024 from $50.67 million in fiscal year 2023.
• Gross profit decreased to $3.88 million in fiscal year 2024 from $4.06 million in the previous year.
• The company's revenue is heavily concentrated, with approximately 90% of consolidated net sales coming from two customers.
• The company is experiencing negative impacts on margins due to inflation and tightened labor markets.
• The company's profit margins decreased slightly from 8.0% to 7.7% in fiscal year 2024.

Risks

• The loss of any of the company's major customers could have a significant adverse impact on its financial condition and results of operations.
• Supply chain disruptions resulting from geopolitical events could impact the company's financial results and ability to ship products.
• The company's indebtedness may decrease its flexibility, increase borrowing costs, and adversely affect liquidity.
• Complying with new and existing government regulations could increase costs significantly and adversely affect financial results.
• The company may be exposed to legal proceedings initiated by regulators or third parties.
• The company depends on its senior management, and the loss of any of them would have an adverse effect.
• The company could be the target of a cybersecurity breach.
• There is no assurance that the company will remain quoted or listed on an active trading market.
• The company has entered into several transactions with entities controlled by some of its officers and directors, which could pose a conflict of interest.
• The company's executive officers and directors have majority voting power and may take actions that may not be in the best interest of other stockholders.
• The company has a staggered Board of Directors, which could impede an attempt to acquire the company or remove management.
• The company's product liability insurance may be insufficient to cover possible claims against it.
• The company may not be able to obtain raw materials used in certain of its manufactured products.
• Current economic conditions may cause a decline in business and consumer spending.
• The company may incur significant professional service fees and other control costs.
• If the company discovers material weaknesses in its internal control, its stock price could decline.
• The company has not paid dividends on its common stock and does not expect to in the foreseeable future.
• A sale of a substantial number of shares of the company's common stock may cause the price to decline.
• Investors' expectations of the company's performance relating to environmental, social, and governance factors may impose additional costs and expose it to new risks.

Future Outlook

Management believes that operations, together with the revolving credit facility and equipment financing, will support working capital requirements at least through the twelve-month period ending September 20, 2025.

Management Comments

• We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base.
• We are currently experiencing negative impacts on our margins due to inflation and tightened labor markets.

Industry Context

The nutraceutical industry is highly competitive, with many larger companies having greater financial resources. The company intends to compete by stressing the quality of its manufactured products, providing prompt service, competitive pricing, and focusing on niche products in international retail markets.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects.
• The company's reliance on two major customers for 90% of its revenue is a significant concentration risk, which is not uncommon in contract manufacturing but is higher than some industry benchmarks.
• The company's gross profit margin of 7.7% is relatively low compared to some branded nutraceutical companies, but may be typical for contract manufacturers.
• The company's return to profitability is a positive sign, but its dependence on a few key customers and exposure to supply chain and economic risks are areas of concern.

Related Party Transactions

• The company leases warehouse and office facilities from Vitamin Realty Associates, LLC, which is owned by the estate of the company's former chairman and certain family members who are also Co-Chief Executive Officers and directors of the company.

Stakeholder Impact

• Shareholders will be impacted by the company's return to profitability and the potential risks outlined in the report.
• Employees are impacted by the company's financial performance and the collective bargaining agreement with the Teamsters Union.
• Customers are impacted by the company's ability to maintain supply and competitive pricing.
• Suppliers are impacted by the company's ability to maintain relationships and purchase raw materials.

Next Steps

• The company will continue to focus on its core businesses and maintain its cost structure.
• The company will work to expand its customer base.
• The company will monitor and address the negative impacts on margins due to inflation and tightened labor markets.

Key Dates

Keywords

nutraceuticals, contract manufacturing, vitamins, nutritional supplements, herbal products, financial results, revenue, profit, operating income, net income, supply chain, regulation, risk factors